---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-001319"
form_type: "8-K"
ticker: "PROF"
cik: "0001628808"
company_name: "Profound Medical Corp."
filed_at: "2025-03-07T23:59:59+00:00"
generated_at: "2026-05-25T03:43:55.746838+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Profound Medical restates Q1-Q3 2024 financials due to $472k revenue error; Q4 revenue up 108% YoY

## Summary
- Revenue overstated by $472k in Q1 2024; prior 6-K filings for Q1-Q3 2024 no longer reliable.
- Q4 2024 revenue $4.2M (+108% YoY); net loss $4.9M ($0.20/share) vs $8.9M ($0.42) in Q4 2023.
- Full year 2024 revenue $10.7M; net loss $27.8M ($1.12/share) vs $28.3M ($1.34) in 2023.
- New $10M CIBC revolving credit line matures March 2027; option to increase to $15M if trailing revenue exceeds $15M.
- Mathieu Burtnyk promoted to President; Tom Tamberrino appointed CCO; CAPTAIN trial enrollment complete.

## SEC filing metadata
- accession: 0001171843-25-001319
- form_type: 8-K
- ticker: PROF
- cik: 0001628808
- company_name: Profound Medical Corp.
- filed_at: 2025-03-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.02, 2.03, 4.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628808/000117184325001319/0001171843-25-001319-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628808/000117184325001319/f8k_030725.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-001319
- JSON: https://secwatch.observer/filing/0001171843-25-001319.json
- Plain text: https://secwatch.observer/filing/0001171843-25-001319.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.